The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101. Beyond its mental health applications, NRX-101 shows promise as a non-opioid ...

This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...

Lorna Staines discusses a longitudinal population-based study examining the risks of using psychedelics in a naturalistic ...

A child facing verbally or physically abusive treatment at home or school who has no means of escaping continuing injury is at elevated risk for developing depression. Situations may not be ...